Gold bars to be exempt from tariffs, White House clarifies
Investing.com - RBC Capital raised its price target on Insulet Corporation (NASDAQ:PODD) to $350.00 from $330.00 on Friday, while maintaining an Outperform rating on the insulin delivery system maker. The medical device company, currently valued at $21.93 billion, has demonstrated robust financial health with a "GREAT" rating according to InvestingPro analysis.
The price target increase follows Insulet’s strong quarterly performance, with the company reporting revenue and earnings per share that beat expectations by 6% and 27%, respectively. The company maintains impressive revenue growth of 23.49% and a healthy gross margin of 70.39%.
Insulet also raised its full-year 2025 revenue and operating margin guidance, and introduced third-quarter guidance that significantly exceeded consensus estimates.
RBC Capital noted that Insulet’s Omnipod 5 remains the most prescribed automated insulin delivery system in the United States and leads in new customer acquisitions in both the U.S. and European markets.
The firm highlighted Insulet’s strong market position, stating the company continues to gain market share in an "highly under-penetrated market" with its "best-in-class product offering, market access, and execution."
In other recent news, Insulet Corporation reported impressive second-quarter results for 2025, significantly surpassing both earnings and revenue forecasts. The company achieved an earnings per share (EPS) of $1.17, well above the projected $0.92, and reported revenue of $649 million, exceeding expectations of $614.18 million. This performance marked a 31% year-over-year growth. Following these results, Jefferies raised its price target for Insulet to $375, maintaining a Buy rating. Canaccord Genuity also increased its price target to $353, citing strong growth and improved guidance for fiscal year 2025. Bernstein raised its price target to $400, highlighting Insulet’s consistent growth and projecting the continuation of over 20% growth in constant currency through 2025. The company’s robust performance was driven by increased new patient starts in both U.S. Type 1 and Type 2 diabetes markets, as well as international markets. These developments have contributed to a positive outlook from multiple analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.